Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 09, 2025, titled "Glenmark Pharmaceuticals to Launch DCGI-approved BRUKINSA? in India to Advance Treatment of Hematological Malignancies".
Press Release Jun 09 2025
Filed with NSE · · 4 pages · English
Summary by 6ix AI
Glenmark Pharmaceuticals Limited has announced the upcoming launch of BRUKINSA® in India, following approval by the Drugs Controller General of India. BRUKINSA® is a treatment for various hematological malignancies and is the first Bruton’s tyrosine kinase inhibitor approved in India for multiple B-cell cancers. This launch represents a significant milestone in Glenmark's oncology portfolio, aimed at addressing the unmet needs of patients with blood cancers in India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Glenmark Pharmaceuticals Limited on 6ix
Earlier from Glenmark Pharmaceuticals
- Press Release Jun 02 2025
- Press Release May 23 2025
- Press Release May 05 2025
- Press Release Apr 16 2025
- Press Release Apr 01 2025
Later from Glenmark Pharmaceuticals
- Press Release Jun 24 2025
- Glenmark Launches a Transformative Nutrition and Livelihood Project in Emali, Kenya
- Press Release Jul 10 2025
- Press Release Aug 14 2025
- Glenmark Pharmaceuticals Inc., USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial)
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals